[{"sentence":{"sentenceText":"In a first aspect, the invention provides fully human mono-\nclonal antibodies (mAbs) and antigen-binding fragments\nthereof that specifically bind and neutralize human PCSK9\n(hPCSK9) activity.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In one embodiment, the invention comprises an antibody or\nantigen-binding fragment of an antibody that specifically\nbinds hPCSK9 and is characterized by at least one of:\n(I) capable of reducing serum total cholesterol at least\nabout 25-35% and sustaining the reduction over at least a 24\n5\n10\n15\n20\n25\n30\n35\n40\n45\n50\n55\n60\n65\nday period relative to a predose level, preferably the reduction\nin serum total cholesterol is at least about 30-40%;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"(ii) capable of reducing serum LDL cholesterol at least\nabout 65-80% and sustaining the reduction over at least a 24\nday period relative to a predose level;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"(iii) capable of reducing serum triglyceride at least about\n25-40% relative to predose level;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"(iv) does not reduce serum HDL cholesterol or reduces\nserum HDL cholesterol no more than 5% relative to predose\nlevel.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In one embodiment, the invention comprises an antibody or\nantigen-binding fragment of an antibody that specifically\nbinds hPCSK9 and is characterized by at least one of:\n(I) capable of reducing serum LDL cholesterol at least\nabout 40-70% and sustaining the reduction over at least a 60\nor 90 day period relative to a predose level;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"(ii) capable of reducing serum triglyceride at least about\n25-40% relative to predose level;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"(iii) does not reduce serum HDL cholesterol or reduces\nserum HDL cholesterol no more than 5% relative to predose\nlevel.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In one embodiment, the antibody or antigen-binding frag-\nment is characterized as binding an epitope comprising amino\nacid residue 238 of hPCSK9 (SEQ ID NO:755).","extractedSEQ":["238","755"]}},{"sentence":{"sentenceText":"In a more\nspecific embodiment, the antibody or antigen-binding frag-\nment binds an epitope comprising one or more of amino acid\nresidue 238, 153, 159 and 343 of hPCSK9 (SEQ ID\nNO:755).).","extractedSEQ":["238","153","159","343","755"]}},{"sentence":{"sentenceText":"In a more specific embodiment, the antibody or\nfragment thereof is characterized as binding an epitope which\ndoes not comprise an amino acid residue at position 192, 194,\n197 and\/or 237 of SEQ ID NO:755.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In one embodiment, the antibody or antigen-binding frag-\nment is characterized as binding an epitope comprising amino\nacid residue 366 of hPCSK9 (SEQ ID NO:755).","extractedSEQ":["366","755"]}},{"sentence":{"sentenceText":"In a more\nspecific embodiment, the antibody or antigen-binding frag-\nment binds an epitope comprising one or more of amino acid\nresidue at position 147, 366 and 380 of SEQ ID NO:755.","extractedSEQ":["147","366","380","755"]}},{"sentence":{"sentenceText":"In a\nmore specific embodiment, the antibody or antigen-binding\nfragment of an antibody is characterized as binding an\nepitope which does not comprise an amino acid residue at\nposition 215 or 238 of SEQ ID NO:755.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In one embodiment, the antibody or antigen-binding frag-\nment is characterized as exhibiting an enhanced binding\naffinity (K~) for hPCSK9 at pH 5.5 relative to the K~ at pH\n7.4, as measured by plasmon surface resonance.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In a specific\nembodiment, the antibody or fragment thereof exhibits at\nleast a 20-fold, at least a 40-fold or at least a 50-fold enhanced\naffinity for PCSK9 at an acidic pH relative to a neutral pH, as\nmeasured by surface plasmon resonance.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In one embodiment, the antibody or antigen-binding frag-\nment is characterized as not exhibiting an enhanced binding\naffinity for PCSK9 at an acidic pH relative to a neutral pH, as\nmeasured by surface plasmon resonance.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In a specific\nembodiment, the antibody or fragment thereof exhibits a\ndecreased binding affinity at an acidic pH.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In another embodiment, the antibody or antigen-binding\nfragment binds human, human GOF mutation D374Y, cyno-\nmolgus monkey, rhesus monkey, mouse, rat and hamster\nPCSK9.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In one embodiment, the antibody or antigen-binding frag-\nment binds human and monkey PCSK9, but does not bind\nmouse, rat or hamster PCSK9.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"The mAbs can be full-length (e.g.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":", an IgGI or IgG4 anti-\nbody) or may comprise only an antigen-binding portion (e.g.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":",\na Fab, F(ab')~ or scFv fragment), and may be modified to\naffect functionality, e.g.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":", to eliminate residual effector func-\ntions (Reddy et al.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"(2000) J.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"Immunol.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"164:1925-1933).","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"US 8,501,184 B2\nIn one embodiment, the invention comprises an antibody or\nantigen-binding fragment of an antibody comprising a heavy\nchain variable region (HCVR) selected from the group con-\nsisting of SEQ ID NO:2, 18, 22, 26, 42, 46, 50, 66, 70, 74, 90,\n94, 98, 114, 118, 122, 138, 142, 146, 162, 166, 170, 186, 190,\n194, 210, 214, 218, 234, 238, 242, 258, 262, 266, 282, 286,\n290, 306, 310, 314, 330, 334, 338, 354, 358, 362, 378, 382,\n386, 402, 406, 410, 426, 430, 434, 450, 454, 458, 474, 478,\n482, 498, 502, 506, 522, 526, 530, 546, 550, 554, 570, 574,\n578, 594, 598, 602, 618, 622, 626, 642, 646, 650, 666, 670,\n674, 690, 694, 698, 714, 718, 722, 738 and 742, or a substan-\ntially similar sequence thereof having at least 90%, at least\n95%, at least 98% or at least 99% sequence identity.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In one\nembodiment, the HCVR comprises an amino acid sequence\nselected from the group consisting of SEQ ID NO:50, 66, 70,\n74, 90, 94, 122, 138, 142, 218, 234, 238, 242, 258, 262, 314,\n330 and 334.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In a more specific embodiment, the HCVR\ncomprises SEQ ID NO:90 or 218.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In one embodiment, the antibody or fragment thereof fur-\nther comprises a light chain variable region (LCVR) selected\nfrom the group consisting of SEQ ID NO:10, 20, 24, 34, 44,\n48, 58, 68, 72, 82, 92, 96, 106, 116, 120, 130, 140, 144, 154,\n164, 168, 178, 188, 192, 202, 212, 216, 226, 236, 240, 250,\n260, 264, 274, 284, 288, 298, 308, 312, 322, 332, 336, 346,\n356, 360, 370, 380, 384, 394, 404, 408, 418, 428, 432, 442,\n452, 456, 466, 476, 480, 490, 500, 504, 514, 524, 528, 538,\n548, 552, 562, 572, 576, 586, 596, 600, 610, 620, 624, 634,\n644, 648, 658, 668, 672, 682, 692, 696, 706, 716, 720, 730,\n740 and 744, or a substantially similar sequence thereof hav-\ning at least 90%, at least 95%, at least 98% or at least 99%\nsequence identity.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In one embodiment, the LCVR comprises\nan amino acid sequence selected from the group consisting of\nSEQ ID NO: 58, 68, 72, 82, 92, 96, 130, 140, 144, 226, 236,\n240, 250, 260, 264, 322, 332 and 336.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In a more specific\nembodiment, the LCVR comprises SEQ ID NO:92 or 226.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In specific embodiments, the antibody or fragment thereof\ncomprises a HCVR and LCVR (HCVR\/LCVR) sequence\npair selected from the group consisting of SEQ ID NO: 2\/10,\n18\/20, 22\/24, 26\/34, 42\/44, 46\/48, 50\/58, 66\/68, 70\/72, 74\/82,\n90\/92, 94\/96, 98\/106, 114\/116, 118\/120, 122\/130, 138\/140,\n142\/144, 146\/154, 162\/164, 166\/168, 170\/178, 186\/188, 190\/\n192, 194\/202, 210\/212, 214\/216, 218\/226, 234\/236, 238\/240,\n242\/250, 258\/260, 262\/264, 266\/274, 282\/284, 286\/288, 290\/\n298, 306\/308, 310\/312, 314\/322, 330\/332, 334\/336, 338\/346,\n354\/356, 358\/360, 362\/370, 378\/380, 382\/384, 386\/394, 402\/\n404, 406\/408, 410\/418, 426\/428, 430\/432, 434\/442, 450\/452,\n454\/456, 458\/466, 474\/476, 478\/480, 482\/490, 498\/500, 502\/\n504, 506\/514, 522\/524, 526\/528, 530\/538, 546\/548, 550\/552,\n554\/562, 570\/572, 574\/576, 578\/586, 594\/596, 598\/600, 602\/\n610, 618\/620, 622\/624, 626\/634, 642\/644, 646\/648, 650\/658,\n666\/668, 670\/672, 674\/682, 690\/692, 694\/696, 698\/706, 714\/\n716, 718\/720, 722\/730, 738\/740 and 742\/744.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In one embodi-\nment, the HCVR and LCVR sequence pair comprises one of\nSEQ ID NO: 50\/58, 66\/68, 70\/72, 74\/82, 90\/92, 94\/96, 122\/\n130, 138\/140, 142\/144, 218\/226, 234\/236, 238\/240, 242\/250,\n258\/260, 262\/264, 314\/322, 330\/332 and 334\/336.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In a more\nspecific embodiment, the HCVR\/LCVR pair comprises SEQ\nID NO:90\/92 or 218\/226.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In a second aspect, the invention features an antibody or\nantigen-binding fragment of an antibody comprising a heavy\nchain CDR3 (HCDR3) domain selected from the group con-\nsisting of SEQ ID NO:8, 32, 56, 80, 104, 128, 152, 176, 200,\n224, 248, 272, 296, 320, 344, 368, 392, 416, 440, 464, 488,\n512, 536, 560, 584, 608, 632, 656, 680, 704 and 728, or a\nsubstantially similar sequence thereof having at least 90%, at\nleast 95%, at least 98% or at least 99% sequence identity;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"and\na light chain CDR3 (LCDR3) domain selected from the group\n5\n10\n15\n20\n25\n30\n35\n40\n45\n50\n55\n60\n65\nconsisting of SEQ ID NO:16, 40, 64, 88, 112, 136, 160, 184,\n208, 232, 256, 280, 304, 328, 352, 376, 400, 424, 448, 472,\n496, 520, 544, 568, 592, 616, 640, 664, 688, 712 and 736, or\nsubstantially similar sequences thereof having at least 90%, at\nleast 95%, at least 98% or at least 99% sequence identity.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In\none embodiment, the HCDR3\/LCDR3 sequence pair is\nselected from the group consisting of SEQ ID NO:56\/64,\n80\/88, 128\/136, 224\/232, 248\/256 and 320\/328.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In a more\nspecific embodiment, the HCDR3\/LCDR3 sequence pair\ncomprises SEQ ID NO:80\/88 or 224\/232.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In a further embodiment, the invention comprising an anti-\nbody or fragment thereof further comprising a heavy chain\nCDRI (HCDRI) domain selected from the group consisting\nof SEQ ID NO:4, 28, 52, 76, 100, 124, 148, 172, 196, 220,\n244, 268, 292, 316, 340, 364, 388, 412, 436, 460, 484, 508,\n532, 556, 580, 604, 628, 652, 676, 700 and 724, or a substan-\ntially similar sequence thereof having at least 90%, at least\n95%, at least 98% or at least 99% sequence identity;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"a heavy\nchain CDR2 (HCDR2) domain selected from the group con-\nsisting of SEQ ID NO:6, 30, 54, 78, 102, 126, 150, 174, 198,\n222, 246, 270, 294, 318, 342, 366, 390, 414, 438, 462, 486,\n510, 534, 558, 582, 606, 630, 654, 678, 702 and 726, or a\nsubstantially similar sequence thereof having at least 90%, at\nleast 95%, at least 98% or at least 99% sequence identity;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"a\nlight chain CDRI (LCDRI) domain selected from the group\nconsisting of SEQ ID NO:12, 36, 60, 84, 108, 132, 156, 180,\n204, 228, 252, 276, 300, 324, 348, 372, 396, 420, 444, 468,\n492, 516, 540, 564, 588, 612, 636, 660, 684, 708 and 732, or\na substantially similar sequence thereof having at least 90%,\nat least 95%, at least 98% or at least 99% sequence identity;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"and a light chain CDR2 (LCDR2) domain selected from the\ngroup consisting of SEQ ID NO:14, 38, 62, 86, 110, 134, 158,\n182, 206, 230, 254, 278, 302, 326, 350, 374, 398, 422, 446,\n470, 494, 518, 542, 566, 590, 614, 638, 662, 686, 710and734,\nor a substantially similar sequence thereof having at least\n90%, at least 95%, at least 98% or at least 99% sequence\nidentity.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In one embodiment, the heavy and light chain CDR\nsequences comprise a sequence selected from the group con-\nsisting ofSEQ ID NO:52, 54, 56, 60, 62, 64;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"76, 78, 80, 84, 86,\n88;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"124, 126, 128, 132, 134, 136;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"220, 222, 224, 228, 230,\n232;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"244, 246, 248, 252, 254, 256;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"and 316, 318, 320, 324,\n326, 328.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In more specific embodiments, the CDR sequences\ncomprise SEQ ID NO: 76, 78, 80, 84, 86, 88;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"or 220, 222, 224,\n228, 230, 232.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In a related embodiment, the invention comprises an anti-\nbody or antigen-binding fragment of an antibody which spe-\ncifically binds hPCSK9, wherein the antibody or fragment\ncomprises heavy and light chain CDR domains contained\nwithin heavy and light chain sequence pairs selected from the\ngroup consisting of SEQ ID NO: 2\/10, 18\/20, 22\/24, 26\/34,\n42\/44, 46\/48, 50\/58, 66\/68, 70\/72, 74\/82, 90\/92, 94\/96,\n98\/106, 114\/116, 118\/120, 122\/130, 138\/140, 142\/144, 146\/\n154, 162\/164, 166\/168, 170\/178, 186\/188, 190\/192, 194\/202,\n210\/212, 214\/216, 218\/226, 234\/236, 238\/240, 242\/250, 258\/\n260, 262\/264, 266\/274, 282\/284, 286\/288, 290\/298, 306\/308,\n310\/312, 314\/322, 330\/332, 334\/336, 338\/346, 354\/356, 358\/\n360, 362\/370, 378\/380, 382\/384, 386\/394, 402\/404, 406\/408,\n410\/418, 426\/428, 430\/432, 434\/442, 450\/452, 454\/456, 458\/\n466, 474\/476, 478\/480, 482\/490, 498\/500, 502\/504, 506\/514,\n522\/524, 526\/528, 530\/538, 546\/548, 550\/552, 554\/562, 570\/\n572, 574\/576, 578\/586, 594\/596, 598\/600, 602\/610, 618\/620,\n622\/624, 626\/634, 642\/644, 646\/648, 650\/658, 666\/668, 670\/\n672, 674\/682, 690\/692, 694\/696, 698\/706, 714\/716, 718\/720,\n722\/730, 738\/740 and 742\/744.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In one embodiment, the CDR\nsequences are contained within HCVR and LCVR selected\nfrom the amino acid sequence pairs of SEQ ID NO: 50\/58,\n66\/68, 70\/72, 74\/82, 90\/92, 94\/96, 122\/130, 138\/140, 142\/\nUS 8,501,184 B2\n144, 218\/226, 234\/236, 238\/240, 242\/250, 258\/260, 262\/264,\n314\/322, 330\/332 and 334\/336.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In more specific embodi-\nments, the CDR sequences are comprised within HCVR\/\nLCVR sequences selected from SEQ ID NO: 90\/92 or 218\/\n226.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In one embodiment, the invention provides fully human\nmonoclonal antibody or antigen-binding fragment thereof\nthat specifically bind hPCSK9 and neutralize PCSK9 activity,\nwherein the antibody or fragment thereof exhibits one or\nmore of the following characteristics: (I) capable of reducing\nserum total cholesterol at least about 25-35% and sustaining\nthe reduction over at least a 24 day period relative to a predo se\nlevel, preferably the reduction in serum total cholesterol is at\nleast about 30-40%;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"(ii) capable of reducing serum LDL\ncholesterol at least about 65-80% and sustaining the reduc-\ntion over at least a 24 day period relative to a predose level;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"(iii) capable of reducing serum triglyceride at least about\n25-40% relative to predose level;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"(iv) does not reduce serum\nHDL cholesterol or reduces serum HDL cholesterol no more\nthan 5% relative to predose level;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"(v) binds an epitope com-\nprising amino acid residue 238 of hPCSK9 (SEQ ID\nNO:755);","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"(vi) exhibits an enhanced binding affinity (K~) for\nhPCSK9 at p H 5.5 relative to the K~ at p H 7.4, as measured by\nplasmon surface resonance, wherein the enhanced affinity is\nat least about a 20- to 50-fold increase in afiinity;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"(vii) binds\nhuman, human GOF mutation D374Y, cynomolgus monkey,\nrhesus monkey, mouse, rat and hamster PCSK9;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"(viii) com-\nprises heavy and light chain CDR3 sequences comprising\nSEQ ID NO:80 and 88;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"and (ix) comprises CDR sequences\nfrom SEQ ID NO:90 and 92.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In one embodiment, the invention provides fully human\nmonoclonal antibody or antigen-binding fragment thereof\nthat specifically bind human PCSK9 (hPCSK9) and neutral-\nize PCSK9 activity, wherein the antibody or fragment thereof\nexhibits one or more of the following characteristics: (I)\ncapable of reducing serum LDL cholesterol at least about\n40-70% and sustaining the reduction over at least a 60 or 90\nday period relative to a predose level;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"(ii) capable of reducing\nserum triglyceride at least about 25-40% relative to predose\nlevel;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"(iii) does not reduce serum HDL cholesterol or reduces\nserum HDL cholesterol no more than 5% relative to predose\nlevel;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"(iv) binds an epitope comprising amino acid residue\n366 of hPCSK9 (SEQ ID NO:755);","extractedSEQ":["366","755"]}},{"sentence":{"sentenceText":"(v) does not exhibit an\nenhanced binding affinity for PCSK9 at an acidic pH relative\nto a neutral pH, as measured by surface plasmon resonance;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"(vi) binds human and monkey PCSK9, but does not bind\nmouse, rat or hamster PCSK9;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"(vii) comprises heavy and light\nchain CDR3 sequences comprising SEQ ID NO:224 and 232;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"and (viii) comprises CDR sequences from SEQ ID NO:218\nand 226.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In a third aspect, the invention provides nucleic acid mol-\necules encoding anti-PCSK9 antibodies or fragments thereof.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"Recombinant expression vectors carrying the nucleic acids of\nthe invention, and host cells into which such vectors have\nbeen introduced, are also encompassed by the invention, as\nare methods ofproducing the antibodies by culturing the host\ncells under conditions permitting production of the antibod-\nies, and recovering the antibodies produced.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In one embodiment, the invention provides an antibody or\nfragment thereof comprising a HCVR encoded by a nucleic\nacid sequence selected from the group consisting of SEQ ID\nNO: I, 17, 21, 25, 41, 45, 49, 65, 69, 73, 89, 93, 97, 113, 117,\n121, 137, 141, 145, 161, 165, 169, 185, 189, 193, 209, 213,\n217, 233, 237, 241, 257, 261, 265, 281, 285, 289, 305, 309,\n313, 329, 333, 337, 353, 357, 361, 377, 381, 385, 401, 405,\n409, 425, 429, 433, 449, 453, 457, 473, 477, 481, 497, 501,\n505, 521, 525, 529, 545, 549, 553, 569, 573, 577, 593, 597,\n5\n10\n15\n20\n25\n30\n35\n40\n45\n50\n55\n60\n65\n601, 617, 621, 625, 641, 645, 649, 665, 669, 673, 689, 693,\n697, 713, 717, 721, 737 and 741, or a substantially identical\nsequence having at least 90%, at least 95%, at least 98%, or at\nleast 99%homology thereof.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In one embodiment, the HCVR\nis encoded by a nucleic acid sequence selected from the group\nconsisting of SEQ ID NO: 49, 65, 69, 73, 89, 93, 121, 137,\n141, 217, 233, 237, 241, 257, 261, 313,329 and 333.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In more\nspecific embodiments, the HCVR is encoded by a nucleic\nacid sequence selected from the group consisting of SEQ ID\nNO: 89 and 217.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In one embodiment, the antibody or fragment thereof fur-\nther comprises a LCVR encoded by a nucleic acid sequence\nselected from the group consisting of SEQ ID NO: 9, 19, 23,\n33, 43, 47, 57, 67, 71, 81, 91,95, 105, 115,119,129, 139, 143,\n153, 163, 167, 177, 187, 191, 201, 211, 215, 225, 235, 239,\n249, 259, 263, 273, 283, 287, 297, 307, 311,321, 331, 335,\n345, 355, 359, 369, 379, 383, 393, 403, 407, 417, 427, 431,\n441, 451, 455, 465, 475, 479, 489, 499, 503, 513, 523, 527,\n537, 547, 551, 561, 571, 575, 585, 595, 599, 609, 619, 623,\n633, 643, 647, 657, 667, 671, 681, 691, 695, 705, 715, 719,\n729, 739 and 743, or a substantially identical sequence having\nat least 90%, at least 95%, at least 98%, or at least 99%\nhomology thereof.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In one embodiment, the LCVR is encoded\nby a nucleic acid sequence selected from the group consisting\nofSEQ ID NO: 57, 67, 71, 81, 91, 95, 129, 139, 143, 225, 235,\n239, 249, 259, 263, 321, 331 and 335.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In more specific\nembodiments, the LCVR is encoded by a nucleic acid\nsequence selected from the group consisting of SEQ ID NO:\n91 and 225.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In one embodiment, the invention features an antibody or\nantigen-binding fragment of an antibody comprising a\nHCDR3 domain encoded by a nucleotide sequence selected\nfrom the group consisting of SEQ ID NO:7, 31, 55, 79, 103,\n127, 151, 175, 199, 223, 247, 271, 295, 319, 343, 367, 391,\n415, 439, 463, 487, 511, 535, 559, 583, 607, 631, 655, 679,\n703 and 727, or a substantially identical sequence having at\nleast 90%, at least 95%, at least 98%, or at least 99%homol-\nogy thereof;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"and a LCDR3 domain encoded by a nucleotide\nsequence selected from the group consisting of SEQ ID NO:\n15, 39, 63, 87, 111, 135, 159, 183, 207, 231, 255, 279, 303,\n327, 351, 375, 399, 423, 447, 471, 495, 519, 543, 567, 591,\n615, 639, 663, 687, 711 and 735, or a substantially identical\nsequence having at least 90%, at least 95%, at least 98%, or at\nleast 99% homology thereof.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In one embodiment, the\nHCDR3 and LCDR3 comprise a sequence pair encoded by\nthe nucleic acid sequence of SEQ ID NO: 55\/63, 79\/87,\n127\/135, 223\/231, 247\/255 and 319\/327, respectively.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In\nmore specific embodiments, the HCDR3 and LCDR3 com-\nprise a sequence pair encoded by the nucleic acid sequence of\nSEQ ID NO: 79\/87 and 223\/231.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In a further embodiment, the antibody or fragment thereof\nfurther comprises, a HCDRI domain encoded by a nucleotide\nsequence selected from the group consisting of SEQ ID NO:\n3, 27, 51, 75, 99, 123, 147, 171, 195, 219, 243, 267, 291, 315,\n339, 363, 387, 411, 435, 459, 483, 507, 531, 555, 579, 603,\n627, 651, 675, 699 and 723, or a substantially identical\nsequence having at least 90%, at least 95%, at least 98%, or at\nleast 99%homology thereof;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"a HCDR2 domain encoded by a\nnucleotide sequence selected from the group consisting of\nSEQ ID NO:5, 29, 53, 77, 101, 125, 149, 173, 197, 221, 245,\n269, 293, 317, 341, 365, 389, 413, 437, 461, 485, 509, 533,\n557, 581, 605, 629, 653, 677, 701 and 725, or a substantially\nidentical sequence having at least 90%, at least 95%, at least\n98%, or at least 99% homology thereof;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"a LCDRI domain\nencoded by a nucleotide sequence selected from the group\nconsisting of SEQ ID NO: 11,35, 59, 83, 107, 131, 155, 179,\n203, 227, 251, 275, 299, 323, 347, 371, 395, 419, 443, 467,\nUS 8,501,184 B2\n491, 515, 539, 563, 587, 611, 635, 659, 683, 707 and 731, or\na substantially identical sequence having at least 90%, at least\n95%, at least 98%, or at least 99% homology thereof;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"and a\nLCDR2 domain encoded by a nucleotide sequence selected\nfrom the group consisting of SEQ ID NO: 13,37, 61, 85, 109,\n133, 157, 181, 205, 229, 253, 277, 301, 325, 349, 373, 397,\n421, 445, 469, 493, 517, 541, 565, 589, 613, 637, 661, 685,\n709 and 733, or a substantially identical sequence having at\nleast 90%, at least 95%, at least 98%, or at least 99%homol-\nogy thereof.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In one embodiment, the heavy and light chain\nCDR sequences are encoded by the nucleic acid sequences of\nSEQ ID NO: 51, 53, 55, 59, 61, 63;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"75, 77, 79, 83, 85, 87;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"123,\n125, 127, 131, 133, 135;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"219, 221, 223, 227, 229, 231;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"243,\n245, 247, 251, 253, 255;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"and315, 317,319,323, 325, 327.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In\nmore specific embodiments, the heavy and light chain CDR\nsequences are encoded by the nucleic acid sequences of SEQ\nID NO: 75, 77, 79, 83, 85, 87;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"and 219, 221, 223, 227, 229,\n231.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In a fourth aspect, the invention features an isolated anti-\nbody or antigen-binding fragment thereof that specifically\nbinds hPCSK9, comprising a HCDR3 and a LCDR3, wherein\nHCDR3 comprises an amino acid sequence of the formula\nX'-X -X -X -X -X -X -X -X -X' -X\"-X' -X' -X' -X'-\nX -X -X -X -X (SEQ ID NO:747), wherein X js Ala,\nX isArgorLys, X isAsp, X is SerorIle, X isAsnorVal,\nX is Leuor Trp, X is GlyorMet, X isAsnorVal, X is Phe\nor Tyr, X' is Asp, X\"is Leu or Met, X' is Asp or absent, X'\nis Tyrorabsent, X' is Tyror absent, X' is Tyrorabsent, X'\nis Tyrorabsent, X' isGlyorabsent, X' isMetorabsent, X'\nis Asp or absent, and X is Val or absent;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"and LCDR3 com-\nprises an amino acid sequence of the formula X'-X -X -X-\nX -X -X -X -X (SEQ ID NO:750), wherein X' is Gln or\nMet, X is Gln, X is Tyr or Thr, X is Tyr or Leu, X is Thr or\nGln, X is Thr, X is Pro, X is Tyr or Leu, and X is Thr.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In a further embodiment, the antibody or fragment thereof\nfurther comprise a HCDRI sequence of the formula X'-X-\nX -X -X -X -X -X (SEQ ID NO:745), wherein X' is Gly,\nX is Phe, X is Thr, X is Phe, X is SerorAsn, X is Seror\nAsn, X is Tyror His, andX isAlaor Trp;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"a HCDR2 sequence\nof the formula X -X -X -X -X -X -X -X (SEQ ID\nNO:746), whereinX' is Ile, X is SerorAsn, X is GlyorGln,\nX isAsporSer, X is Gly, X is SerorGly, X is ThrorGlu,\nand X is Thr or Lys;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"a LCDRI sequence of the formula\nX'-X -X -X -X -X -X -X -X -X' -X\"-X' (SEQ ID\nNO:748) wherein X' is Gln, X is Ser, X is Val or Leu, X is\nLeu, X is His or Tyr, X is Arg or Ser, X is Ser or Asn, X is\nAsnorGly, X isAsn, X' isArgorAsn, X\"isAsnor Tyr, and\nX' is Phe or absent;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"a LCDR2 sequence of the formula\nX'-X -X (SEQ ID NO:749) wherein X' is Trp orLeu, X is\nAla or Gly, and X is Ser.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"FIG.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"1 shows the sequence align-\nment of heavy and light chain variable regions for 316P and\n300N mAbs.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In a fifth aspect, the invention features a human anti-\nPCSK9 antibody or antigen-binding fragment of an antibody\ncomprising a heavy chain variable region (HCVR) encoded\nby nucleotide sequence segments derived from V~, Dem and J~\ngermline sequences, and a light chain variable region\n(LCVR) encoded by nucleotide sequence segments derived\nfrom V~ and J~ germline sequences, wherein the germline\nsequences are (a) V~ gene segment 3-23, D~ gene segment\n7-27, J~ gene segment 2, V~ gene segment 4-1 and J~ gene\nsegment 2;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"or (b) V~ gene segment 3-7, D~ gene segment 2-8,\nJ~ gene segment 6, V~ gene segment 2-28 and J~ gene seg-\nment 4.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In a sixth aspect, the invention features an antibody or\nantigen-binding fragment thereof that binds to a PCSK9 pro-\ntein of SEQ ID NO:755, wherein the binding of the antibody\n5\n10\n15\n20\n25\n30\n35\n40\n45\n50\n55\n60\n65\nor fragment thereof to a variant PCSK9 protein is less than\n50% of the binding between the antibody or fragment thereof\nand the PCSK9 protein of SEQ ID NO:755.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In specific\nembodiment, the antibody or fragment thereof binds to the\nvariant PCSK9 protein with a binding affinity (K~) which is\nless than about 50%, less than about 60%, less than about\n70%, less than about 80%, less than about 90% or less than\nabout 95% compared to the binding to PCSK9 (SEQ ID\nNO:755).","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In one embodiment, the variant PCSK9 protein comprises\nat least one mutation at position 238 of SEQ ID NO:755.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In a\nmore specific embodiment, the mutation is D238R.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In one\nembodiment, the antibody or antibody fragment binding\naffinity for the variant PCSK9 protein is at least 90% less\nrelative to the wildtype protein of SEQ ID NO:755, wherein\nthe variant protein comprises a mutation at residue 238.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In one\nembodiment, the antibody or antibody fragment binding\naffinity for the variant PCSK9 protein is at least 80% less\nrelative to the wildtype protein of SEQ ID NO:755, wherein\nthe variant protein comprises a mutation at one or more of\nresidue 153, 159, 238 and 343.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In a more specific embodi-\nment, the mutation is one of S153R, E159R, D238R and\nD343R.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In one embodiment, the variant PCSK9 protein comprises\nat least one mutation at position 366 of SEQ ID NO:755.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In a\nmore specific embodiment, the mutation is E366K.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In one\nembodiment, the antibody or antibody fragment binding\naffinity for the variant PCSK9 protein is at least 95% less\nrelative to the wildtype protein of SEQ ID NO:755, wherein\nthe variant protein comprises a mutation at residue 366.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In one\nembodiment, the antibody or antibody fragment binding\naffinity for the variant PCSK9 protein is at least 90% less\nrelative to the wildtype protein of SEQ ID NO:755, wherein\nthe variant protein comprises a mutation at one or more of\nresidue 147, 366 and 380.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In a more specific embodiment, the\nmutation is one ofS147F,E366Kand V380M.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In one embodi-\nment, the antibody or antibody fragment binding affinity for\nthe variant PCSK9 protein is at least 80% less relative to the\nwildtype protein of SEQ ID NO:755, wherein the variant\nprotein comprises a mutation at one or more of residue 147,\n366 and 380.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In a more specific embodiment, the mutation is\none of S147F, E366K and V380M.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"The invention encompasses anti-PCSK9 antibodies having\na modified glycosylation pattern.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In some applications, modi-\nfication to remove undesirable glycosylation sites may be\nuseful, or e.g.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":", removal of a fucose moiety to increase anti-\nbody dependent cellular cytotoxicity (ADCC) function (see\nShield et al.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"(2002) JBC 277:26733).","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In other applications,\nmodification of galactosylation can be made in order to\nmodify complement dependent cytotoxicity (CDC).","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In a seventh aspect, the invention features a pharmaceutical\ncomposition comprising a recombinant human antibody or\nfragment thereof which specifically binds hPCSK9 and a\npharmaceutically acceptable carrier.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In one embodiment, the\ninvention features a composition which is a combination ofan\nantibody or antigen-binding fragment of an antibody of the\ninvention, and a second therapeutic agent.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"The second thera-\npeutic agent may be any agent that is advantageously com-\nbined with the antibody or fragment thereof of the invention,\nfor example, an agent capable of inducing a cellular depletion\nof cholesterol synthesis by inhibiting 3-hydroxy-3-methyl-\nglutaryl (HMG)-coenzyme A (CoA) reductase, such as, for\nexample, cerovastatin, atorvastatin, simvastatin, pitavastin,\nrosuvastatin, fluvastatin, lovastatin, pravastatin, etc.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"capable\nof inhibiting cholesterol uptake and or bile acid re-absorp-\ntion;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"capable of increasing lipoprotein catabolism (such as\nUS 8,501,184 B2\n10\nniacin);","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"and\/or activators of the LXR transcription factor that\nplays a role in cholesterol elimination such as 22-hydroxyc-\nhole sterol.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In an eighth aspect, the invention features methods for\ninhibiting hPCSK9 activity using the anti-PCSK9 antibody or\nantigen-binding portion of the antibody of the invention,\nwherein the therapeutic methods comprise administering a\ntherapeutically effective amount of a pharmaceutical compo-\nsition comprising an antibody or antigen-binding fragment of\nan antibody of the invention.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"The disorder treated is any\ndisease or condition which is improved, ameliorated, inhib-\nited or prevented by removal, inhibition or reduction of\nPCSK9 activity.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"Specific populations treatable by the thera-\npeutic methods of the invention include subjects indicated for\nLDL apheresis, subjects with PCSK9-activating mutations\n(gain of function mutations, \"GOF\"), subjects with heterozy-\ngous Familial Hypercholesterolemia (heFH);","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"subjects with\nprimary hypercholesterolemia who are statin intolerant or\nstatin uncontrolled;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"and subjects at risk for developing hyper-\ncholesterolemia who may be preventably treated.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"Other indi-\ncations include dyslipidemia associated with secondary\ncauses such as Type 2 diabetes mellitus, cholestatic liver\ndiseases (primary biliary cirrhosis), nephrotic syndrome,\nhypothyroidism, obesity;","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"and the prevention and treatment of\natherosclerosis and cardiovascular diseases.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"In specific embodiments ofthe method ofthe invention, the\nanti-hPCSK9 antibody or antibody fragment of the invention\nis useful to reduce elevated total cholesterol, non-HDL cho-\nlesterol, LDL cholesterol, and\/or apolipoprotein B (apolipo-\nprotein B100).","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"The antibody or antigen-binding fragment of the invention\nmay be used alone or in combination with a second agent, for\nexample, an HMG-CoA reductase inhibitor and\/or other lipid\nlowering drugs.","extractedSEQ":["noData"]}},{"sentence":{"sentenceText":"Other embodiments will become apparent from a review of\nthe ensuing detailed description.","extractedSEQ":["noData"]}}]